you're right. RIGL def. has a few new things going on, like that asthma drug. last investor conference presentation I sat in, the company really kept focusing on the asthma drug in the pipeline.
After the RA drug the asthma drug is in the most developed state and that's in P1 or probably P2. Everything else is pre-clinical. And the asthma drug was dropped by PFE. The asthma drug probably still has potential but the fact that it is inhaled likely means increased regulatory risk.